A Phase 2 interventional study of Placebo and Benralizumab 25 mg in Asthma, sponsored by MedImmune LLC. Completed at 6 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-27.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 33rd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 4th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 199th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2008, is one of 50 in phase 2, and was the 113th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
This is a Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of multiple subcutaneous doses (25, 100, or 200 milligram [mg]) of benralizumab (MEDI-563) in adult subjects with asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
Other: Placebo
Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
Biological: Benralizumab 25 mg
Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
Biological: Benralizumab 100 mg
Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
Biological: Benralizumab 200 mg
Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
Also known as: MEDI-563
Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
Also known as: MEDI-563
Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
Also known as: MEDI-563
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.
Time frame: Day 0 to Day 161
Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab
Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Maximum Observed Serum Concentration (Cmax) for Benralizumab
Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab
Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.
Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Terminal Phase Elimination Half-Life (t1/2) for Benralizumab
Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.
Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit
Time frame: Day 0, 28, 56, 84, 112, and 161
| Milestone | Placebo | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|---|
| Started | 6 | 7 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.
| participants | Placebo | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|---|
| TEAEs | 3 | 4 | 4 | 4 |
| TESAEs | 0 | 0 | 0 | 0 |
| days | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab | 7.00 (7.00 to 28.00) | 7.00 (1.00 to 7.00) | 7.00 (7.00 to 7.00) |
| microgram per milliliter (mcg/mL) | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) for Benralizumab | 1.152 ± 0.615 | 4.127 ± 1.775 | 15.637 ± 8.062 |
Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.
| microgram*day per milliliter | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|
| Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab | 118.335 ± 69.640 | 405.868 ± 205.856 | 1157.013 ± 86.444 |
Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.
| days | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|
| Terminal Phase Elimination Half-Life (t1/2) for Benralizumab | 17.163 ± 2.368 | 18.610 ± 3.905 | 18.315 ± 3.484 |
| participants | Placebo | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|---|
| Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit | 0 | 1 | 1 | 2 |
Collected over Day 0 to Day 161. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/6 (0%) | 3/6 (50%) |
| Benralizumab 25 mg | — | 0/7 (0%) | 4/7 (57.1%) |
| Benralizumab 100 mg | — | 0/6 (0%) | 4/6 (66.7%) |
| Benralizumab 200 mg | — | 0/6 (0%) | 4/6 (66.7%) |
| Event | Placebo | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg |
|---|---|---|---|---|
| Oral candidiasisInfections and infestations | 2/6 | 0/7 | 0/6 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 0/7 | 1/6 | 2/6 |
| HeadacheNervous system disorders | 0/6 | 0/7 | 2/6 | 0/6 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/6 | 2/7 | 0/6 | 1/6 |
| PyrexiaGeneral disorders | 0/6 | 0/7 | 0/6 | 1/6 |
| Gastrointestinal viral infectionInfections and infestations | 0/6 | 0/7 | 0/6 | 1/6 |
| Oral herpesInfections and infestations | 0/6 | 0/7 | 0/6 | 1/6 |
| Respiratory tract infection viralInfections and infestations | 0/6 | 0/7 | 0/6 | 1/6 |
| SinobronchitisInfections and infestations | 0/6 | 0/7 | 0/6 | 1/6 |
| Viral infectionInfections and infestations | 1/6 | 0/7 | 1/6 | 0/6 |
Intent-to-treat (ITT) population included all participants randomized into the study.
| Age, Continuous(years) | Placebo | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 45.7 ± 11.2 | 50.4 ± 12.3 | 45.5 ± 13.4 | 40.2 ± 12.5 | 45.6 ± 12.2 |
| Sex: Female, Male(Participants) | Placebo | Benralizumab 25 mg | Benralizumab 100 mg | Benralizumab 200 mg | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 4 | 3 | 14 |
| Male | 3 | 3 | 2 | 3 | 11 |
Ran from Nov 2008 to primary completion in Nov 2009, 12 months.
Results were first posted in Dec 2019, 10 years 1 month after primary completion. A results delay was requested in Jun 2012.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab